Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111.

Authors:

Abstract
6049 Background: Targeted agents (TA) are often investigated in unselected end-stage cancer patients (pts), making difficult to fully evaluate their activity and impairing translational research. One way to resolve this issue is to perform "window" studies where a TA is given between the diagnosis and surgery. Afatinib (A) is an oral ErbB family blocker that improves PFS of pts with recurrent SCCHN after platinum failure. Methods: This study was a randomized, multicenter, phase II window of opportunity trial. Treatment-naïve SCCHN pts selected for primary curative surgery were randomized (5:1 ratio) to receive A during 14 days (day -15 until day -1) before surgery (day 0) or no treatment (B). Tumour biopsies, FDG/PET, and MRI were performed at diagnosis and at surgery. The primary end point was metabolic FDG-PET/CT response (centrally reviewed; H0 = 10%, H1 = 30%, Alpha = 10% 1-sided, Power = 90%); according to EORTC guidelines). Other endpoints included response by RECIST, DCE MRI, DWI MRI, and translational research. Results: 30 pts were randomized in 4 centers: 25 to A and 5 to B. 23 pts randomized to A were eligible (median age: 59, male/female: 16/7, oral cavity/oropharynx: 19/4; ECOG 0/1: 15/8, stage II/III/IV: 4/4/15). One pt discontinued A after 11 days for gr3 renal failure and diarrhea with delayed surgery by 24 days. Another pt had gr3 acneiform rash. Of the 24 pts who completed the planned A treatment, 2 had delayed surgery by 4 and 2 days (gr2 colitis and organizational issues). No surgical complications were related to A. Of the 23 eligible pts, 16 had a partial metabolic FDG/PET response (PMR): 70% (95% CI: 47-87%). There were no complete responses and 7 pts had stable disease (SMD). The proportion of responders to A was significantly higher than 10% (p < 0.001). There was no CMR/PMR in the no-treatment arm (n = 3). Conclusions: This study demonstrates that multinational challenging window studies are feasible. Preliminary results show that A given for 2 weeks to newly diagnosed SCCHN pts induces a high rate of FDG-PET response and can be safely administered before surgery. Definitive results will be presented at ASCO 2016. Translational research to evaluate predictive biomarkers is ongoing Clinical trial information: NCT01538381.